Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?

Renal cell carcinoma (RCC) comprises a highly heterogeneous group of kidney tumours built upon distinct genetic- and epigenetic-driven mechanisms and molecular pathways. Therefore, responsiveness to treatment is considerably variable across patients, adding an extra layer of complexity to the alread...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontes-Sousa, Mário, Magalhães, Helena, Oliveira, Alicia, Carneiro, Filipa, dos Reis, Filipa Palma, Madeira, Pedro Silvestre, Meireles, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756748/
https://www.ncbi.nlm.nih.gov/pubmed/35025061
http://dx.doi.org/10.1007/s12325-021-02007-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756748/
https://www.ncbi.nlm.nih.gov/pubmed/35025061
http://dx.doi.org/10.1007/s12325-021-02007-y

Ejemplares similares